Revvity (RVTY) revenue breakdown
By segment, Life Sciences is the largest at 50% of fiscal 2025 revenue; Diagnostics grew fastest, 10% a year over 9 years.
By product, Product is the largest at 84% of fiscal 2025 revenue, growing 6% a year over 9 years.
Revenue by segment
Fiscal years, as Revvity reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences | $1.5B | $1.6B | $1.7B | $1.7B | $596M | $896M | $1.3B | $1.5B | $1.4B | $1.4B | 50% |
| Diagnostics | $603M | $679M | $1.1B | $1.1B | $2.1B | $2.9B | $2.0B | $1.3B | $1.4B | $1.4B | 50% |
Revenue by product
Fiscal years, as Revvity reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $1.4B | $1.5B | $1.9B | $2.0B | $2.3B | $2.7B | $2.6B | $2.4B | $2.3B | $2.4B | 84% |
| Service | $719M | $780M | $843M | $867M | $382M | $1.1B | $677M | $335M | $417M | $466M | 16% |
Revenue by region
Fiscal years, as Revvity reports them in its 10-K filings; fiscal 2025 total $2.9B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | — | — | — | $1.1B | $1.0B | $1.8B | $1.7B | $1.2B | $1.2B | $1.3B | 44% |
| Europe | — | — | — | $787M | $1.0B | $1.2B | $832M | $747M | $743M | $825M | 29% |
| Asia | — | — | — | $977M | $604M | $804M | $817M | $788M | $789M | $775M | 27% |
| UNITED STATES | — | — | $906M | — | — | — | — | — | — | — | — |
| UNITED STATES | $842M | — | — | — | — | — | — | — | — | — | — |
| UNITED STATES | — | $837M | — | — | — | — | — | — | — | — | — |
| Other International | — | — | $672M | — | — | — | — | — | — | — | — |
| Other International | — | $569M | — | — | — | — | — | — | — | — | — |
| CHINA | — | — | $560M | — | — | — | — | — | — | — | — |
| Other International | $529M | — | — | — | — | — | — | — | — | — | — |
| CHINA | — | $375M | — | — | — | — | — | — | — | — | — |
| CHINA | $337M | — | — | — | — | — | — | — | — | — | — |
| GERMANY | — | — | $142M | — | — | — | — | — | — | — | — |
| FRANCE | — | — | $98M | — | — | — | — | — | — | — | — |
| ITALY | — | — | $96M | — | — | — | — | — | — | — | — |
| INDIA | — | — | $92M | — | — | — | — | — | — | — | — |
| GERMANY | — | $92M | — | — | — | — | — | — | — | — | — |
| GERMANY | $90M | — | — | — | — | — | — | — | — | — | — |
| INDIA | — | $85M | — | — | — | — | — | — | — | — | — |
| FRANCE | — | $80M | — | — | — | — | — | — | — | — | — |
| JAPAN | — | — | $79M | — | — | — | — | — | — | — | — |
| ITALY | — | $77M | — | — | — | — | — | — | — | — | — |
| JAPAN | — | $76M | — | — | — | — | — | — | — | — | — |
| UNITED KINGDOM | — | — | $72M | — | — | — | — | — | — | — | — |
| FRANCE | $71M | — | — | — | — | — | — | — | — | — | — |
| ITALY | $71M | — | — | — | — | — | — | — | — | — | — |
| JAPAN | $66M | — | — | — | — | — | — | — | — | — | — |
| UNITED KINGDOM | $66M | — | — | — | — | — | — | — | — | — | — |
| UNITED KINGDOM | — | $65M | — | — | — | — | — | — | — | — | — |
| KOREA, REPUBLIC OF | — | — | $60M | — | — | — | — | — | — | — | — |
| INDIA | $44M | — | — | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RVTY.
Open RVTY in InvestinglyQuestions
Where does Revvity make its money?
In fiscal 2025, by segment: Life Sciences $1.4B, Diagnostics $1.4B.
From Revvity's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.